A robust pipeline of TRuC-T cell therapies for solid and hematologic cancers
We are developing a wide range of cell therapies for solid tumors as well as blood cancers by targeting a number of different surface antigens on cancer cells that have beneficial expression characteristics. We are also supplementing our basic TRuC-T cell format with innovative enhancements to combat the hostile tumor microenvironment in case certain cancer indications prove more resistant.
Our most advanced program, gavo-cel, targets tumors that express the protein mesothelin, including ovarian cancer, non-small cell lung cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Our preclinical programs are a combination of additional novel targets, technological enhancements for autologous therapies, and the expansion of TRuC-T cells into autoimmune diseases. We have also developed an allogeneic (“off-the-shelf”) TRuC-T cell.
- Innovations in Progress
Progress: Phase 2
Progress: Phase 1
NSCLC: non-small cell lung cancer; MPM: malignant pleural/peritoneal mesothelioma; aALL: adult acute lymphoblastic leukemia; DLBCL: diffuse large B-cell lymphoma; NHL: other non-Hodgkin lymphoma (NHL) subtypes including follicular lymphoma (FL), mantle cell lymphoma (MCL), primary mediastinal B-cell lymphoma (PMBCL)
Innovations in Progress
We continue to broaden our platform through internal research and collaboration with leading academic laboratories and industry partners. These innovations fall into three broad categories: